Sabine Altrichter: Influence Statistics

Sabine Altrichter

Sabine Altrichter

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany | Division of Dermatological Allergy, Department of ...

Sabine Altrichter: Expert Impact

Concepts for which Sabine Altrichter has direct influence: Chronic spontaneous urticaria , Cholinergic urticaria , Chronic urticaria , Autoimmune diseases , Csu patients , Total ige , Physical urticarias .

Sabine Altrichter: KOL impact

Concepts related to the work of other authors for which for which Sabine Altrichter has influence: Chronic urticaria , Atopic dermatitis , Mast cells , Omalizumab treatment , Patients csu , Schnitzler syndrome , Allergic diseases .

KOL Resume for Sabine Altrichter

Year
2022

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany

Universitätsklinikum für Dermatologie und Venerologie, Kepler Uniklinikum Linz, Linz, Austria

Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, 8000, Denmark

2021

Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany

Department of Dermatology und Venerology, Comprehensive Allergy Center, Kepler University Hospital, Krankenhausstraße 9, 4020 Linz, Austria

2020

Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Department of Dermatology and Allergy, Allergie-Centrum-Charité/ECARF, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

2019

Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Berlin

2018

Department of Dermatology and Allergology, Charité ‐ Universitätsmedizin Berlin, Berlin, Germany

Allergie‐Centrum‐Charité, Urticaria Center of Reference and Excellence (UCARE), Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin

2017

Charité – Universitätsmedizin Berlin Department of Dermatology and Allergy Berlin Germany

2016

Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.

2015

Department of Dermatology and Allergy; Allergie-Centrum-Charité; Charité - Universitätsmedizin Berlin; Berlin Germany

2014

Department of Dermatology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany

2013

Charité – Universitätsmedizin Berlin Department of Dermatology and Allergology Berlin Germany

2012

Charité – Universitätsmedizin Berlin Department of Dermatology and Allergy, Allergie‐Centrum‐Charité Berlin Germany

2011

Charité–Universitätsmedizin Berlin, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany

2010

Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité–Universitätsmedizin Berlin, Berlin, Germany

Klinik für Dermatologie, Venerologie und Allergologie, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland

2009

Department of Dermatology and Allergy, Allergie‐Centrum‐Charité/ECARF, Charité‐Universitätsmedizin Berlin, Berlin, Germany*

2008

Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DIAID), Medical University of Vienna, Vienna, Austria

2007

Department of Dermatology and Allergy, Charité‐Universitätsmedizin Berlin, Berlin, Germany

Prominent publications by Sabine Altrichter

KOL-Index: 14438 . BACKGROUND: A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) ...
Known for Omalizumab Patients | Monoclonal Antibodies | Chronic Urticaria | 24 Weeks
KOL-Index: 11979 . BACKGROUND: Chronic spontaneous urticaria (csU), which is characterized by recurrent episodes of mast cell-driven wheal and flare-type skin reactions, is often associated with elevated total IgE levels and thyroid autoimmunity. We speculate that some csU patients express IgE autoantibodies against thyroid antigens such as thyroid peroxidase (TPO), which could bind to skin mast cells and ...
Known for Thyroid Peroxidase | Chronic Spontaneous Urticaria | Csu Patients | Tpo Ige
KOL-Index: 9827 . Patients with chronic spontaneous urticaria (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of ...
Known for Chronic Spontaneous Urticaria | Patients Csu | Thyroid Diseases | Elevated Levels
KOL-Index: 9209 . BACKGROUND: Chronic spontaneous urticaria (CSU) is characterized by the degranulation of skin mast cells and the influx of basophils and eosinophils to affected skin sites. Blood basopenia has been linked to severe antihistamine-resistant CSU and type IIb autoimmunity, whereas the role of eosinophils in CSU is largely unknown. OBJECTIVE: To analyze data from 1613 patients with CSU from 2 ...
Known for Chronic Spontaneous Urticaria | Poor Response | Patients Csu | Basophil Counts
KOL-Index: 8020 . BACKGROUND: IgG autoantibodies against the high-affinity IgE receptor, FcɛRIα, contribute the pathogenesis of autoimmune chronic spontaneous urticaria (CSU). However, it is not known whether such patients also exhibit IgM or IgA autoantibodies against FcɛRIα. To address this question we developed an ELISA to assess serum levels of IgG, IgM, and IgA autoantibodies against FcɛRIα and ...
Known for Igg Autoantibodies | Patients Csu | Chronic Spontaneous Urticaria | Elevated Levels
KOL-Index: 7894 . BACKGROUND: Elevated levels of C-reactive protein (CRP), a sensitive marker of inflammation, have been consistently reported in chronic spontaneous urticaria (CSU). Here, we retrospectively analyzed data from 1253 CSU patients from 2 centers to answer the following questions: (i) What is the prevalence of elevated levels of CRP in CSU? (ii) Why do CSU patients show elevated levels of CRP? ...
Known for Chronic Spontaneous Urticaria | Patients Csu | Reactive Protein | Quality Life
KOL-Index: 7174 . BACKGROUND: Matrix metalloproteinase (MMP)-9, an enzyme that contributes to inflammatory responses and subsequent tissue remodelling, has recently been suggested to be a good biomarker for monitoring disease activity in patients with chronic urticaria (CU). Here, we assessed whether total MMP-9 and/or active MMP-9 plasma levels are increased and correlated to disease activity in patients ...
Known for Chronic Urticaria | Matrix Metalloproteinase | Mmp9 Levels | Patients Healthy Controls
KOL-Index: 6648 . OBJECTIVE: Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets. DATA SOURCES: MEDLINE was searched for recent reports ...
Known for Chronic Urticaria | Promising Targets | Omalizumab Treatment | Antibodies Monoclonal
KOL-Index: 6540 . Background Cholinergic urticaria (CholU), a frequent type of chronic inducible urticaria, presents with small itchy wheals upon physical exercise or passive warming. Omalizumab has been shown to be very effective in patients with chronic spontaneous urticaria. Whether or not omalizumab is also effective in CholU is largely unknown. Aim To assess the effectiveness of omalizumab treatment ...
Known for Cholinergic Urticaria | Life Treatment | Cholu Patients | Passive Warming
KOL-Index: 6463 . BACKGROUND: The guidelines recommend that first line treatment of chronic spontaneous urticaria should be second generation non-sedating H(1)-antihistamines with a positive recommendation against the use of old sedating first generation antihistamines. If standard dosing is not effective, increasing the dosage up to four-fold is recommended. The objective of this study was to obtain the ...
Known for Chronic Spontaneous Urticaria | Standard Doses | Unwanted Effects | Generation Antihistamines
KOL-Index: 6341 . OBJECTIVE: Immunoglobulin E (IgE) and its receptor, FcɛRI, importantly contribute to the pathophysiology of chronic spontaneous urticaria (CSU). Recent findings point to a possible role of total IgE as a marker of CSU disease activity, endotypes, and responses to treatment. The evidence in support of total IgE included in the diagnostic workup of patients with CSU has not yet been ...
Known for Total Ige | Chronic Spontaneous Urticaria | Csu Patients | Omalizumab Treatment
KOL-Index: 6315 . PURPOSE: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid autoimmune diseases. METHODS: We analyzed records of CSU patients (n = 1,199) for a history or presence of autoimmune ...
Known for Csu Patients | Type Iib | Autoimmune Diseases | Chronic Spontaneous
KOL-Index: 5917 . In physical urticaria, exogenous physical factors such as thermal triggers, solar radiation and mechanic triggers including friction or pressure are responsible for the elicitation of symptoms in the skin of patients. Avoidance of the respective stimulus is usually difficult or impossible, and many patients are not sufficiently treated with standard antihistamines. We report that treatment ...
Known for Monoclonal Antibodies | Physical Urticaria | Treatment Omalizumab | Humanized Female
KOL-Index: 5795 . BACKGROUND: Schnitzler syndrome (SchS) is a rare disease with suspected autoinflammatory background that shares several clinical symptoms, including urticarial rash, fever episodes, arthralgia, and bone and muscle pain with cryopyrin-associated periodic syndromes (CAPS). Cryopyrin-associated periodic syndromes respond to treatment with interleukin-1 antagonists, and single case reports of ...
Known for Patients Schs | Schnitzler Syndrome | Urticarial Rash | Inflammatory Markers
KOL-Index: 5750 . BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent disorder with recurrent itchy wheals and/or angioedema. Despite the known effectiveness of omalizumab therapy, the relevant IgE antigens are largely unknown. Recently, increased rates of elevated levels of IgE towards Staphylococcus aureus enterotoxins (SEs) were described in CSU. AIM: To assess the prevalence and functional ...
Known for Chronic Spontaneous Urticaria | Csu Patients | Ige Levels | Omalizumab Therapy

Key People For Chronic Spontaneous Urticaria

Top KOLs in the world
#1
Marcus Maurer
mast cells chronic spontaneous urticaria hereditary angioedema
#2
Sarbjit Singh Saini
chronic urticaria antiidiotypic antibodies mast cells
#3
Ana Maria Giménez‐Arnau
chronic urticaria contact dermatitis patch testing
#4
Torsten Zuberbier
allergic rhinitis chronic urticaria mast cells
#5
Petra Staubach
chronic urticaria hereditary angioedema patients csu
#6
Carsten Bindslev Bindslev‐Jensen
histamine release allergic rhinitis atopic dermatitis

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany | Division of Dermatological Allergy, Department of Dermatology, Venerology and Allergy, Charité – Universitätsmedizin Berlin, corpor